Literature DB >> 2759035

Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secretion from porcine parathyroid cells in culture.

B H Fasciotto1, S U Gorr, D J DeFranco, M A Levine, D V Cohn.   

Abstract

Chromogranin-A, also referred to as secretory protein-I, is a 50K protein found in and secreted by endocrine cells, in which it is costored with the native hormone. Porcine chromogranin-A contains a sequence identical to pancreastatin, a 49-amino acid, C-terminally amidated peptide that has been isolated from porcine pancreas, suggesting that chromogranin-A is the precursor of pancreastatin. Pancreastatin has been found to be a potent inhibitor of glucose-stimulated insulin release. As it is possible that pancreastatin inhibits secretion from other chromogranin-A-containing tissues in which it may be formed, we tested its action on dispersed porcine parathyroid cells in culture. Secretion of chromogranin-A and PTH was up to 6-fold greater at 0.5 mM Ca2+ than at 3.0 mM Ca2+. Pancreastatin (1 nM) reduced the secretion of both chromogranin-A and PTH at 0.5 mM Ca2+ to approximately the levels found at 3.0 mM Ca2+, but did not affect secretion at 3.0 mM Ca2+. Pancreastatin (0.01-1.0 nM) inhibited secretion of chromogranin-A in a dose-dependent fashion. Preincubation of the cells with pancreastatin was not required for inhibition. Transfer of inhibited cells to medium without pancreastatin led to restoration of secretion within 90 min. Phorbol myristate acetate (1.6 microM) stimulated secretion of PTH and chromogranin-A at 3.0 mM Ca2+, but not at 0.5 mM Ca2+. Pancreastatin reversed this stimulation, demonstrating that its inhibition was independent of Ca2+ concentration. These results are consonant with pancreastatin playing a physiological role in modulation of secretion by the parathyroid and, by extension, other endocrine tissues.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759035     DOI: 10.1210/endo-125-3-1617

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-jing Wang; Robert Elashoff; Barbara Gales; Mara J Horwitz; Andrew F Stewart; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

Review 2.  The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors.

Authors:  P Rosa; H H Gerdes
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

3.  Pancreastatin (33-49) enhances the priming effect of glucose in the rat pancreas.

Authors:  V Sánchez-Margalet; R Goberna
Journal:  Experientia       Date:  1993-07-05

Review 4.  The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.

Authors:  Steven A Feldman; Lee E Eiden
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  The post-translational processing of chromogranin A in the pancreatic islet: involvement of the eukaryote subtilisin PC2.

Authors:  S D Arden; N G Rutherford; P C Guest; W J Curry; E M Bailyes; C F Johnston; J C Hutton
Journal:  Biochem J       Date:  1994-03-15       Impact factor: 3.857

6.  Distribution and coexistence of chromogranin A-, serotonin- and pancreastatin-like immunoreactivity in endocrine-like cells of the human anal canal.

Authors:  D Hörsch; E Weihe; S Müller; E Hancke
Journal:  Cell Tissue Res       Date:  1992-04       Impact factor: 5.249

Review 7.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.